DNLI – denali therapeutics inc. (US:NASDAQ)
Stock Stats
News
Denali Therapeutics (NASDAQ:DNLI) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Denali Therapeutics Unveils Portfolio Goals for 2026, Stock Up [Yahoo! Finance]
Assessing Denali Therapeutics (DNLI) Valuation After Positive Hunter Syndrome Trial Data And FDA Priority Review [Yahoo! Finance]
Denali Therapeutics (NASDAQ:DNLI) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.
Denali Therapeutics (NASDAQ:DNLI) was given a new $25.00 price target on by analysts at UBS Group AG.
Form 4 Denali Therapeutics Inc. For: Jan 06 Filed by: Schuth Alexander O.
Form 4 Denali Therapeutics Inc. For: Jan 06 Filed by: Watts Ryan J.
Form 144 Denali Therapeutics Inc. Filed by: Ho Carole
Form 144 Denali Therapeutics Inc. Filed by: Schuth Alexander O.
Form 144 Denali Therapeutics Inc. Filed by: Watts Ryan J.
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.